Fear of progression in patients with gastrointestinal stromal tumors (GIST): Is extended lifetime related to the Sword of Damocles?

Acta Oncologica

Volumn 54, Issue 8, 2015, Pages 1202-1208

  Custers, José A E ^a   Tielen, Ronald ^a   Prins, Judith B ^a   De Wilt, Johannes H W ^a   Gielissen, Marieke F M ^a   Van Der Graaf, Winette T A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; SUNITINIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CANCER WORRY SCALE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISTRESS SYNDROME; EORTC QUALITY OF LIFE QUESTIONNAIRE; FEAR; FEAR OF CANCER RECURRENCE INVENTORY; FEMALE; FUNCTIONAL DISEASE; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SURGERY; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; IMPACT OF EVENTS SCALE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; SELF REPORT; TUMOR GROWTH; TUMOR RECURRENCE; ANXIETY; DISEASE COURSE; ETIOLOGY; GASTROINTESTINAL STROMAL TUMORS; PSYCHOLOGY; SURVIVOR; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANXIETY; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEAR; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; QUALITY OF LIFE; SURVIVORS; YOUNG ADULT;

EID: 84940562087     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2014.1003960     Document Type: Article

References (25)

1. Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, et al. NCCN Task Force report: Update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw 2010;8(Suppl 2):S1-41; quiz S42-4.
2. Joensuu H. Adjuvant treatment of GIST: Patient selection and treatment strategies. Nat Rev Clin Oncol 2012;9:351-8.
3. Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: A randomised, double-blind, placebo-controlled trial. Lancet 2009;373:1097-104.
4. Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: Origin and molecular oncology. Nat Rev Cancer 2011;11:865-78.
5. Caram MV, Schuetze SM. Advanced or metastatic gastrointestinal stromal tumors: Systemic treatment options. J Surg Oncol 2011;104:888-95.
6. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.
7. Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schutte J, et al. One vs three years of adjuvant imat-inib for operable gastrointestinal stromal tumor: A randomized trial. JAMA 2012;307:1265-72.
8. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 2006;368:1329-38.
9. Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): An international, multicen-tre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381:295-302.
10. Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Flectcher JA, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008;26:620-5.
11. Armes J, Crowe M, Colbourne L, Morgan H, Murrells T, Oakley C, et al. Patients' supportive care needs beyond the end of cancer treatment: A prospective, longitudinal survey. J Clin Oncol 2009;27:6172-9.
12. Mehnert A, Berg P, Henrich G Herschbach P. Fear of cancer progression and cancer-related intrusive cognitions in breast cancer survivors. Psychooncology 2009;18:1273-80.
13. Douma KF, Aaronson NK, Vasen HF, Gerritsma MA, Gundy CM, Janssen EP, et al. Psychological distress and use of psychosocial support in familial adenomatous polyposis. Psychooncology 2010;19:289-98.
14. Ousters JA, van den Berg SW, van Laarhoven HW, Bleiker EM, Gielissen MF, Prins JB. The Cancer Worry Scale: Detecting fear of recurrence in breast cancer survivors. Cancer Nurs 2014;37:E44-50.
15. Simard S, Savard J. Fear of Cancer Recurrence Inventory: Development and initial validation of a multidimensional measure of fear of cancer recurrence. Support Care Cancer 2009;17:241-51.
16. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85: 365-76.
17. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998;16:139-44.
18. Vodermaier A, Millman RD. Accuracy of the Hospital Anxiety and Depression Scale as a screening tool in cancer patients: A systematic review and meta-analysis. Support Care Cancer 2011;19:1899-908.
19. Van der Ploeg E, Mooren TT, Kleber RJ, Van der Velden PG, Brom D. Construct validation of the Dutch version of the impact of event scale. Psychol Assess 2004;16: 16-26.
20. Wiener L, Battles H, Zadeh S, Smith CJ, Helman LJ, Kim SY. Gastrointestinal stromal tumor: Psychosocial characteristics and considerations. Support Care Cancer 2012;20:1343-9.
21. Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, et al. EORTC QLQ-C30 Scoring Manual, 3rd ed. Brussels: EORTC; 2001.
22. Simard S, Thewes B, Humphris G, Dixon M, Hayden C, Mireskandari S, et al. Fear of cancer recurrence in adult cancer survivors: A systematic review of quantitative studies. J Cancer Surviv 2013;7:300-22.
23. Crist JV, Grunfeld EA. Factors reported to influence fear of recurrence in cancer patients: A systematic review. Psychooncology 2013;22:978-86.
24. Macdonald N, Shapiro A, Bender C, Paolantonio M, Coombs J. Experiences and perspectives on the GIST patient journey. Patient Prefer Adherence 2012;6:253-62.
25. Case DO, Andrews JE, Johnson JD, Allard SL. Avoiding versus seeking: The relationship of information seeking to avoidance, blunting, coping, dissonance, and related concepts. J Med Libr Assoc 2005;93:352-62.